Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

Phase I and biomarker study of OPB-51602, a novel signal transducer and activator of transcription (STAT) 3 inhibitor, in patients with refractory solid malignancies

© The Author 2015. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved.Background: The aim of this study was to determine the maximum-tolerated dose (MTD), safety, pharmacokinetics, and pharmacodynamics of OPB-51602, an oral, direct signal...

Full description

Bibliographic Details
Main Authors: Wong, A., Soo, R., Tan, D., Lee, S., Lim, J., Marban, P., Kong, L., Lee, Y., Wang, L., Thuya, W., Soong, R., Yee, M., Chin, T., Cordero, M., Asuncion, B., Pang, B., Pervaiz, Shazib, Hirpara, J., Sinha, A., Xu, W., Yuasa, M., Tsunoda, T., Motoyama, M., Yamauchi, T., Goh, B.
Format: Journal Article
Published: Oxford University Press 2015
Online Access:http://hdl.handle.net/20.500.11937/50956

Internet

http://hdl.handle.net/20.500.11937/50956

Similar Items